Targeting the glycoprotein 130 receptor subunit to control pain and inflammation

Journal of Interferon and Cytokine Research

Volumn 30, Issue 12, 2010, Pages 865-873

  Jazayeri, Jalal A ^a   Upadhyay, Aradhana ^a   Vernallis, Ann B ^b   Carroll, Graeme J ^c,d  

^a MONASH UNIVERSITY   (Australia)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALD 518; ALD518; CILIARY NEUROTROPHIC FACTOR; ELASTIN; GLYCOPROTEIN GP 130; HYBRID PROTEIN; INTERLEUKIN 11; INTERLEUKIN 11 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR ALPHA; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; ONCOSTATIN M; POLYETHYLENE; STAT3 PROTEIN; TOCILIZUMAB; TYROSINE; UNCLASSIFIED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BINDING AFFINITY; BINDING SITE; CELL PROLIFERATION; HUMAN; INFLAMMATION; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINE RECEPTOR GP130; CYTOKINES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PAIN; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 78650001998     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0035     Document Type: Review

References (52)

1. Ancey C, Kuster A, Haan S, Herrmann A, Heinrich PC, Muller- Newen G. 2003. A fusion protein of the gp130 and IL-6Ralpha ligand-binding domains acts as a potent IL-6 inhibitor. J Biol Chem 278(19):16968-16972.
2. Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, Uceyler N, Brockhaus J, Martini R, Sommer C, Zeilhofer HU, Muller W, Kuner R, Davis JB, Rose-John S, Kress M. 2009. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci 29(43):13473-13483.
3. Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Goke B, Ochsenkuhn T. 2005. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J Gastroenterol 11(8):1196-1199.
4. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. 1999. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85(1):134-144.
5. Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N. 2009. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol (Meeting Abstracts) 27(15S):3025.
6. Doganci A, Sauer K, Karwot R, Finotto S. 2005. Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 28(3):257-270.
7. Dubinski A, Zdrojewicz Z. 2007. [The role of interleukin-6 in development and progression of atherosclerosis]. Pol Merkur Lekarski 22(130):291-294.
8. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 67(11):1516-1523.
9. Ernst M, Inglese M, Waring P, Campbell I, Bao S, Clay F, Alexander W, Wicks I, Tarlinton D, Novak U, Heath J, Dunn A. 2001. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 194(2):189-203.
10. Febbraio MA. 2007. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 117(4):841-849.
11. Fischer M.,Goldschmitt J.,Peschel C.,Brakenhoff J.P.,Kallen K.J.,Wollmer A.,Grotzinger J.,Rose-John S., I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion, Nat. Biotechnol., 1997, 15, 2, 142-145
12. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183(5):3170-3176.
13. Grotzinger J, Kernebeck T, Kallen KJ, Rose-John S. 1999. IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 380(7-8):803-813.
14. Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B. 1996. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. J Immunol Methods 190(1):21-27.
15. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2): 297-314.
16. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63(6):1149-1157.
17. Hudson KR, Vernallis AB, Heath JK. 1996. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists. J Biol Chem 271(20):11971-11978.
18. Inta I, Weber D, Grundt C, Veltkamp R, Winteroll S, Auffarth GU, Bettendorf M, Lemmer Br, Schwaninger M. 2009. Correlation of soluble gp130 serum concentrations with arterial blood pressure. J Hypertens 27(3):527-534.
19. Jazayeri JA, Carroll GJ. 2008. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22(1):11-26.
20. Jostock T, Blinn G, Renne C, Kallen KJ, Rose-John S, Mullberg J. 1999. Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. J Immunol Methods 223(2): 171-183.
21. Jostock T, Mü llberg J, Ö zbek S, Atreya R, Blinn G, Voltz N, Fischer M, Markus F, Rose-John S. 2001a. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268(1):160-167.
22. Jostock T, Mü llberg J, Ö zbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. 2001b. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268(1):160-167.
23. Kishimoto T, Akira S, Narazaki M, Taga T. 1995. Interleukin-6 family of cytokines and gp130. Blood 86(4):1243-1254.
24. Kristiansen OP, Mandrup-Poulsen T. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 Suppl 2:S114-S124.
25. Laaksovirta H, Soinila S, Hukkanen V, RÖyttä M, Soilu-Hänninen M. 2008. Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset. Eur J Neurol 15(4):355-359.
26. Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT. 2009. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun 382(2):445-450.
27. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. 2004. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60(4):303-309.
28. Lin M, Rose-John S, Grotzinger J, Conrad U, Scheller J. 2006. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling. Biochem J 398(3):577-583.
29. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. 2008. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58(10):2968-2980.
30. Mochizuki Y, Okamura Y, Iida H, Mori H, Shimada K. 1998. Interleukin-6 and complex cardiac myxoma. Ann Thorac Surg 66(3):931-933.
31. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC. 1998. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161(11):6347-6355.
32. NarazakiM, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. 1993. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82(4):1120-1126.
33. Nishimoto N, Kishimoto T. 2008. Therapeutic antibodies. Berlin, Heidelberg: Springer.
34. Nishimoto N, Kishimoto T, Yoshizaki K. 2000. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59(suppl):i21-i27.
35. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. 2004. Treatment of rheumatoid arthritis with humanized antiinterleukin- 6 receptor antibody: a multicenter, double-blind,placebo-controlled trial. Arthritis Rheum 50(6):1761-1769.
36. Ohtani T, Ishihara K, Akira S, Yamanaka Y, et al. 2000. gp130- mediated signalling as a therapeutic target. Expert Opin Threr Targets 4(4):459-479.
37. Pflanz S, Kurth I, Grotzinger J, Heinrich PC, Muller-Newen G. 2000. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J Immunol 165(12):7042-7049.
38. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3):1021-1028.
39. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi JF, Brochier J, Klein B. 1998. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91(12):4727-4737.
40. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S, Ciliberto G. 1994. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 13(24):5863-5870.
41. Selander KS, Li L, Watson L, Merrell M, Dahmen H, Heinrich PC, Muller-Newen G, Harris KW. 2004. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 64(19):6924-6933.
42. Smith PC,Hobisch A, LinDL, Culig Z,Keller ET. 2001. Interleukin- 6 and prostate cancer progression. Cytokine Growth Factor Rev 12(1):33-40.
43. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. 2000. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 267(1):329-333.
44. Tackey E, Lipsky PE, Illei GG. 2004. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13(5):339-343. (Pubitemid 38788493)
45. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581.
46. Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, Murakami M, Nakao K. 2000. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest 106(1):137-144.
47. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, Rose-John S, Grotzinger J. 2008. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 283(40):27200-27207.
48. Varga VL, Fü lÖp AK, Holub MC, Tó th S, Szalai C, Falus A. 2001. Gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing JUNB mRNAtranscription in the human heptatoma cell line, HEPG2. Cell Biol Int 25(8):835-840.
49. Vernallis AB, Hudson KR, Heath JK. 1997. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M. J Biol Chem 272(43):26947-26952.
50. Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. 2008. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 68(13):1430-1442.
51. Yokota S. 2008. [Interleukin-6 as a pathogenic factor of systemiconset juvenile idiopathic arthritis]. Nihon Rinsho Meneki Gakkai Kaishi 31(2):99-103.
52. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798-809.